TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells by Bartucci, M et al.
ORIGINAL ARTICLE
TAZ is required for metastatic activity and chemoresistance
of breast cancer stem cells
M Bartucci1,7, R Dattilo1,7, C Moriconi1, A Pagliuca1, M Mottolese2, G Federici2, A Di Benedetto2, M Todaro3, G Stassi3, F Sperati2,
MI Amabile4, E Pilozzi5, M Patrizii1, M Biffoni1, M Maugeri-Sacca`2, S Piccolo6 and R De Maria2
Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal
proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell
dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast
cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when
compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating
the disease of patients with early BC, we observed that BCSCs is the only cell population endowed with metastatic potential.
Gene-expression proﬁle studies comparing metastagenic and non-metastagenic cells identiﬁed TAZ, a transducer of the Hippo
pathway and biomechanical cues, as a central mediator of BCSCs metastatic ability involved in their chemoresistance and
tumorigenic potential. Overexpression of TAZ in low-expressing dBCCs induced cell transformation and conferred tumorigenicity
and migratory activity. Conversely, loss of TAZ in BCSCs severely impaired metastatic colonization and chemoresistance. In clinical
data from 99 BC patients, high expression levels of TAZ were associated with shorter disease-free survival in multivariate analysis,
thus indicating that TAZ may represent a novel independent negative prognostic factor. Overall, this study designates
TAZ as a novel biomarker and a possible therapeutic target for BC.
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INTRODUCTION
Breast cancer (BC) is a major public health concern with more than
a million new cases diagnosed annually worldwide.1 Metastatic
growth in distant sites is the predominant cause of death in BC
patients. Growing evidences indicate that a cellular subpopulation
with stem cell (SC)-like features, known as cancer SCs (CSCs), is
critical for tumor generation and maintenance.2–6 In addition,
CSCs have been recently suggested to be responsible for BC
metastasis.7,8 Indeed, it is conceivable that several of the traits
ascribed to CSCs may provide them with the potential to occupy
and prosper at distant sites. Yet, a functional proof of this notion is
currently lacking. To progress in this direction, it is important to
deﬁne, at the molecular level, players and mechanisms conferring
metastatic behavior to CSCs. Here we compared a set of patient-
derived breast cancer SC (BCSC) lines with their differentiated
breast cancer cell (dBCC) progeny.
We found that in vitro BCSCs display enhanced chemoresistance
and migratory capacity than dBCCs. More importantly, by
developing an in vivo metastatic model simulating the natural
course of early BC, we conﬁrmed the exclusive ability of BCSCs to
migrate and grow at secondary sites when compared with dBCCs.
By molecular proﬁling, we identiﬁed the Hippo transducer TAZ as
signiﬁcantly upregulated in metastatic lesions from primary BC
cells. TAZ is involved in enhanced cell proliferation, migration and
transformation.9 Critically, for the present study, TAZ has been
previously shown to serve as a key CSC determinant in BC.10
Intriguingly, TAZ is induced by and mediates the effects of
epithelial-to-mesenchymal-transition, a complex cellular program
well known for its association to epithelial plasticity and BC
stemness.10,11 However, the roles of TAZ-induced CSC potentials in
primary BC metastasis and chemoresistance have not been
explored. In this study, we provide evidence that TAZ is required
for the metastatic ability and chemoresistance of BCSCs.
Moreover, we show that TAZ represents a novel independent
negative prognostic factor in BC. Targeting TAZ and cognate
downstream signaling effectors may therefore have clinical utility
for cancer therapy.
RESULTS
Characterization and validation of breast cancer stem cells (BCSCs)
Starting from primary invasive breast carcinomas (Supplementary
Table S1), we isolated and characterized cells bearing SC
properties. The relative abundance of CD44þ /CD24 /low cells in
BC has an average of 6.12%.12 Thus, following tumor sample
dissociation, cell suspensions were maintained in speciﬁc culture
conditions that allowed the expansion of undifferentiated cancer
stem and progenitor cells, while negatively selecting serum-
dependent tumor and non-transformed accessory cells.13–15 These
cell cultures were essentially composed of the so-called tumor
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‘mammospheres’ (Figure 1a) formed by a majority of CD44þ /
CD24 /low cells, excluding the BCSC#3 cell line highly positive for
the CD44þCD24þproﬁle (Supplementary Figure 1a). BCSCs fail to
express the lineage-speciﬁc markers of two mammary epithelium
compartments, basal cytokeratin 14 (CK14) and luminal cytoker-
atin 18 (CK18)15 (Supplementary Figure 1b). To determine the
in vitro differentiation potential of our patient-derived BCSC lines,
BC spheres were dissociated and grown on collagen. Subse-
quently, cells were covered with matrigel, a culture technique
documented to be more efﬁcient in inducing differentiation of
progenitor cells in cultures.16,17 Under such conditions cells
acquired the typical epithelial-like morphological features
(Figure 1b, left panel). Additionally, exposure to this differentiation
setting resulted in a marked reduction of the clonogenic growth
of these cells in agar, as compared with BCSCs (Figure 1b, right
panel). Consistently, matrigel-differentiated cells expressed either
the basal epithelial marker smooth muscle actin or the luminal
epithelial marker CK 8/18 (Supplementary Figure 1c). These results
revealed that our BC spheres are composed by undifferentiated
cells able to expand in the presence of opportune growth factors
but, under proper conditions, readily generating differentiated BC
cells (dBCCs) resembling the main cellular populations of the
Figure 1. BCSCs are tumorigenic, chemoresistant and migrate more compared with dBCCs. (a) Descriptive pictures of primary human BCSCs
morphology cultured in serum-free conditions (scale bars, 500 mm). (b) Left panel: descriptive images of dBCCs after 3 weeks of culture (scale
bars, 100 mm). Right panel: self-renewal ability of BCSCs vs dBCCs. Mean±s.d. of three independent experiments is shown. (c) Left panel:
representative image showing tumorigenic potential of 5 104 BCSCs (left) as compared with 5 104 dBCCs. Cells were simultaneously
injected into the right and left flank of the same mouse and picture was taken at day 25 after cell injection. Right panel: tumor growth rate
kinetics of xenografts generated following orthotopic injection of BCSC#1, BCSC#4 and BCSC#7 and differentiated counterparts. Three
mice/group were employed. (d) Tumorigenic potential of BCSC#1, BCSC#4 and BCSC#7-derived xenografts assessed by injecting 5 104 cells
into mammary fat pad (secondary xenografts), BCSC spheres derived by such secondary xenografts (tertiary xenografts) and BCSC spheres
derived by tertiary xenografts (quaternary xenografts). Data are mean±s.d. of two different experiments. (e) Cell viability of treated and
untreated (control) BCSCs and corresponding differentiated progeny. Doxorubicin (15 ng/ml) and paclitaxel (5 ng/ml) were added for 48 h and
cell viability was subsequently measured by CellTiter-Glo assay. (f ) Left: illustrative pictures of BCSCs and dBCCs migration capacity. Cell
motility was assessed after 24-h incubation in modified boyden chambers and in serum-free media (scale bars, 1000 mm and 100 mm). Right:
graph showing the number of migrated cells in standard growth conditions. Both the results shown in (e and f ) are the mean±s.d. of three
independent experiments performed by using four different BCSC and dBCC lines.
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breast epithelium. Liquid culture sphere formation analysis
revealed that 12–24% of cells in mammospheres could be
expanded for a number of passages while maintaining tumori-
genic activity (Supplementary Figure 2). To directly compare the
tumorigenic potential of the two cell populations, we injected an
increasing number of BCSCs and dBCCs into the left and right
mammary fat pad of immunodeﬁcient mice, respectively. Xeno-
transplantation of BCSCs resulted in the formation of palpable
tumors within 3–6 weeks, even when as low as 103 cells were
injected (Supplementary Figure 3). While BCSCs were highly
tumorigenic and originated tumors with stable exponential
growth, dBCCs generated tumors at a very low frequency and
only when injected at a high number (Supplementary Figure 3).
Moreover, such dBCC-xenografts were barely able to increase in
size for B3–4 weeks before declining (Figure 1c, right and left
panel). It is important to note that , BCSCs-derived xenograft cells
could be serially transplanted in secondary and tertiary recipients
(Figure 1d).
BCSCs are chemoresistant and possess higher migratory capacity
in vitro
To evaluate CSCs involvement in BC progression, we investigated
chemoresistance and migration capability of patient-derived
BCSCs before and after differentiation in vitro. BCSCs and dBCCs
were exposed to paclitaxel and doxorubicin, two of the most
commonly used chemotherapeutic drugs in BC. Cell viability assay
conﬁrmed a more pronounced drug-induced cytotoxicity in dBCCs
when compared with BCSCs (Figure 1e). Additionally, we assessed
the ‘basal’ aptitude of BCSCs and differentiated progeny to
migrate in modiﬁed Boyden chambers. We found that BCSCs not
only possess a higher migratory capacity than dBCCs, but are also
moderately capable to pass across the polycarbonate membrane
and occupy the lower chamber, thus proving their ability to
invade as well. Conversely, dBCCs migratory potential was almost
undetectable (Figure 1f, left and right panel).
Only BCSCs exhibit metastatic ability in vivo
To overcome the limits of in vitro models and to better understand
metastasis development in vivo, we pursued two different
strategies in mice, both relying on the delivery of combined or
single population of engineered BCSCs and dBCCs. Matched BCSC
lines and dBCCs were differentially transduced with lentiviral
vectors encoding either luciferase/enhanced green ﬂuorescent
protein (Luc/EGFP-BCSCs) or luciferase/red ﬂuorescent protein
(Luc/RFP-dBCCs) reporter genes. Initially, the metastatic rate of
BCSCs and dBCCs was determined upon intracardiac injection.
This approach allows the systemic distribution of the cell
populations to all organs for the analysis of organ-speciﬁc
extravasation, survival in the newly invaded site and retention of
tumor-forming capacity. Mice were inoculated with Luc/EGFP-
BCSCs and Luc/RFP-dBCCs, alone or combined at the deﬁned ratio
of 1:1 (Figure 2a). The appearance of metastatic lesions was then
followed by bioluminescence detection with an in vivo imaging
system. Bioluminescence signals became evident only in
BCSCs-injected mice, alone or combined with Luc/RFP-dBCCs
(Supplementary Figure 4a). Following target organ explants (lungs,
Figure 2. Assessment of metastatic in vivo models and migratory potential of BCSCs. (a) Schematic representation of intracardiac/metastatic
model. Matched BCSC lines and dBCCs were differentially transduced with lentiviral vectors encoding either luciferase/enhanced green
fluorescent protein (Luc/EGFP-BCSCs) or luciferase/red fluorescent protein (Luc/RFP-dBCCs) reporter genes injected alone or combined at a
defined ratio of 1:1. (b) Left: image of a tumor metastasis monitored by bioluminescence imaging (BLI). Right: transmitted-light, fluorescent
stereomicroscopic pictures and H&E staining indicating BC metastasis (black arrows) to the lung (yellow arrow), liver (blue arrow) and to the
bone (white arrow) of NSG mice. (c) Schematic representation of orthotopic/metastatic model. Luc/EGFP-BCSCs and Luc/RFP-dBCCs were
orthotopically injected at a defined ratio of 1:1. After reaching a volume of B300mm3, primary tumors were removed and appearance of
metastases monitored in time. (d) Left: representative BLI of animals showing lung metastases at day 49 after cell injection. Right: transmitted-
light and fluorescent stereomicroscopic pictures of Luc/EGFP-BCSC-derived lung metastases. Immunohistochemistry was performed on
formalin-fixed, paraffin-embedded tissues stained with PanCKs, highlighting the presence of neoplastic cells (black arrow) in the lung of the
mouse (yellow arrow). In all BLI images, the color scale depicts the photon flux (photons per second) emitted.
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liver, bones), stereomicroscopical evaluation detected the pre-
sence of green ﬂuorescent spots, indicating that BCSCs represent
the only population able to generate secondary lesions
(Figure 2b). Nevertheless, it must be taken into consideration
that the metastatic process encompasses a series of steps in which
cancer cells leave the primary site of origin in order to colonize
distant organs. Therefore, we created a more ‘translational’ in vivo
model. The primary tumor was obtained by the orthotopic
injection of differentially labeled BCSCs and dBCCs (1:1 ratio).
Then, to mimic a radical surgical procedure, the tumor was
resected and the onset of metastasis monitored (Figure 2c). Even
on orthotopic injection followed by tumor resection, the only
population capable to generate distant metastases was Luc/EGFP-
BCSCs, as highlighted by the presence of green ﬂuorescent foci
(Figure 2d). Immunoﬂuorescence analysis performed on labeled
BCSCs/dBCCs-derived xenografts revealed that both round and
elongated tubular-like arrangements spotted inside the tumor
mass were entirely formed by Luc/EGFP-BCSCs, which invaded
equally the ducts and the surrounding tissues (Supplementary
Figure 4b). By contrast, Luc/RFP-dBCCs were chaotically distrib-
uted and unable to recreate the mammary tubulo-alveolar
structures. Overall, the development of this in vivo metastatic
model enabled us to validate the preferential ability of patient-
derived BCSCs to migrate and grow at distant sites when
compared with dBCCs.
Molecular proﬁling of BCSCs/dBCCs-derived primary and
metastatic tumors revealed TAZ as a mediator of BCSCs metastasis
Given the differential metastatic ability documented after in vivo
experiments between dBCCs and BCSCs, we searched for genes
potentially responsible for this particular different biological
behavior. To avoid possible biases deriving from in vitro culture
conditions, we generated primary xenografts and subsequent
metastases by injecting the two populations of undifferentiated
and differentiated BC cells into the humanized fat pad. dBCCs,
BCSCs and metastatic BCCs, thereafter referred to as fat pad
differentiated cells (FPD), fat pad stem cells (FPS) and lung
metastases (LMs), respectively, were consequently isolated from
primary and metastatic lesions through ﬂuorescent-activated cell
sorting (Supplementary Figure 5a). A comparative genome-wide
expression study revealed B160 genes differentially expressed in
a pool of the three populations (Supplementary Table S2). To
prioritize these candidate genes and associate their expression
with the metastatic proclivity of BCSCs in vivo, we screened for
genes whose expression in BC was associated with CSCs traits,
focusing on those whose upregulation level followed the rank:
FPS4FPD between the ﬁrst 20 differentially regulated ones
(Figure 3a and Supplementary Table S2). This ‘priority categoriza-
tion’ provided the rationale to explore the role of WWTR1,
also known as the Hippo pathway transducer TAZ, in BCSCs
metastases. This attracted our attention, as TAZ had recently been
shown to induce self-renewal and tumor initiation capacities of BC
stem-like cells derived from immortalized cell lines.10 Similar to
gene expression proﬁling, western blot analyses conﬁrmed that
TAZ protein levels were higher in LM cells than in FPS, whereas in
FPD it was only weakly expressed (Figure 3b). In line with this,
analysis of TAZ expression between distinct primary and meta-
static xenografts revealed that TAZ expression levels were
always considerably higher in tumor metastases (Supplementary
Figure 5b). Moreover, because TAZ activity correlates with nuclear
localization,18 we analyzed several FPS and FPD and found that
TAZ was barely expressed and predominantly cytoplasmic in FPD,
whereas it was abundant and nuclear in FPS (Figure 3c), thus
indicating that TAZ is predominantly active in the metastagenic
cell compartment of a tumor. Consistently, increased levels of TAZ
were associated with increased levels of CTGF and Survivin
(Supplementary Figure 5c), known to be its target genes and to
have an important role in tumorigenesis.19,20
Figure 3. Gene expression profiling reveals TAZ as molecular candidate involved in BCSCs metastatic proclivity. (a) Hierarchical clustering of
statistically differentially expressed genes in fat pad stem (FPS), fat pad differentiated (FPD) and lung metastasis (LMs) cells derived from
orthotopic injection of two different BCSC lines and differentiated counterparts. Distinct cell populations were isolated from primary and
metastatic tumors through fluorescent-activated cell sorting. Each column represents the average of three biological replicates. Color scale
indicates the relative signal intensity. (b) Left: TAZ expression levels in FPS, FPD and LMs derived from the orthotopic injection of BCSCs and
dBCCs #1 and BCSCs and dBCCs #4. MCF-7, MDA-MB-231 and SW620 were employed as positive and negative controls. The relative
densitometric values were normalized over nucleolin, used as loading control (Right panel). A representative of three independent
experiments is shown. (c) Representative immunofluorescent staining on FPS and FPD for TAZ expression and localization. Cells were stained
with phalloidin and DAPI to visualize cell membrane and nuclei. Scale bar, 30 mm.
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TAZ contributes to BCSCs chemoresistance
Resistance to DNA damage-induced apoptosis, motility, invasive-
ness and clonogenicity are relevant in the metastatic process.21
BC generally responds to therapy at the beginning of treatment,
but such responsiveness progressively decreases following
multiple therapeutic regimens.22,23 TAZ has been correlated with
drug resistance in BC cell lines.10,24 Accordingly, metastasis-
derived cells (TAZ overexpressing cells) resulted more resistant
to chemotherapy than the primary tumor-derived cells
(LMs4FPS4FPD) (Figure 4a). To assess the role of TAZ in BCSC
chemoresistance, we performed loss-of-function analyses of TAZ
in BCSCs (Figure 4b and Supplementary Figure 6a). Cell viability
assay revealed that BCSCs controls (BCSCs LKO NT and super GFP)
were considerably more resistant to both paclitaxel- and
doxorubicin-induced cell death than TAZ-depleted cells (BCSCs
LKO shTAZ, shTAZ1 and shTAZ3) (Figure 4c and Supplementary
Figure 6b). Concomitantly, we assessed gain-of-function analyses
of TAZ in dBCCs. In contrast, we observed that overexpression
of TAZ in dBCCs (dBCCs TWEEN TAZ) was not sufﬁcient
to signiﬁcantly counteract chemotherapy-induced cell death
(Figure 4c). Likewise, we evaluated the effect of doxorubicin on
human BC xenografts generated by transplantation of BCSCs LKO
NT and BCSCs LKO shTAZ into NSG mice. Remarkably, silencing of
TAZ enhances the efﬁcacy of chemotherapy in vivo (Figure 4d and
Supplementary Figure 7), thus suggesting that TAZ contributes to
drug resistance in BC.
TAZ supports tumorigenic potential and determines
metastasis-promoting capabilities of BCSCs
To evaluate TAZ involvement in the tumor-seeding ability and
metastatic potential of BCSCs and dBCCs, we compared tumori-
genic capacity of BCSCs LKO shTAZ, dBCCs TWEEN TAZ with their
respective controls (BCSCs LKO NT and dBCCs TWEEN) in
immunodeﬁcient mice. Knocking down TAZ protein levels altered
the growth of primary BCSC-derived tumors when a non-
saturating, low number of cells (50–500), was injected
(Figure 5a). Consequently, we observed that on TAZ overexpres-
sion, dBCCs developed a more spindle-shaped-like appearance
in vitro (Figure 5b) and totally reverted their tumorigenic capacity
in vivo (Figure 5c). Thus, TAZ has a role in the seeding ability of
tumor cells. Crucially, silencing TAZ expression in BCSCs hampered
cell motility in vitro (Figure 5d) and reverted metastasis onset
in vivo, even when up to 5 104 cells/group were injected
(Figure 5e). Accordingly, the motility of TAZ-overexpressing
dBCCs was dramatically enhanced in vitro (approximately ﬁvefold)
and their metastatic ability considerably increased in vivo
(Figures 5d and e).
TAZ protein is overexpressed in BC metastases
The ﬁnding that TAZ was intensely overexpressed in BCSCs-
derived metastases as well as having a critical role in cell migration
and invasion, prompted us to investigate TAZ levels in metastatic
lesions from human BCs. We selected 56 primary BCs (PBCs) with
their paired metachronous metastases. We found that among the
19 TAZ-negative PBCs, only 6 (32%) maintained a concordant
score in the matched metastases, whereas 13 (68%) displayed an
increased TAZ expression level starting from score 1þ (26%),
2þ (32%) and 3þ (10%). Likewise, among the 16 PBCs with a
score of 1þ and the 17 with a score of 2þ , we observed an
increase in TAZ expression in 15 out of 33 (45%) paired
metastases, whereas TAZ expression was lost only in 1 metastatic
lesion derived from a score of 2þ PBC (Figure 6a and Table 1).
Moreover, the analysis of BCSC-derived xenografts showed a clear
increase in TAZ expression in tumor metastases as compared with
the paired primary lesions (Supplementary Figure 5b), thus
conﬁrming the tendency of TAZ to increase in the metastatic site.
TAZ is an independent prognostic marker in BC
Recently, analyses of BC patients gene-expression data sets
correlated TAZ activity with histological grading and higher
probability to develop metastases.10 However, it is unknown
Figure 4. TAZ is involved in BCSCs chemoresistance. (a) Cell viability of BCSCs, dBCCs and corresponding FPS, FPD and LMs on chemotherapy
treatment. Experiments performed starting from three different BCSC lines are shown. (b) Western blot analysis for TAZ expression in cell
lysates from untransduced BCSCs and dBCCs, control vector-transduced (LKO NT and TWEEN), TAZ-depleted (LKO shTAZ) and TAZ-
overexpressing (TWEEN TAZ) cells. b-actin was used to assess equal loading. (c) Chemosensibility evaluated on control vector-transduced
(BCSC LKO NT and dBCC TWEEN), TAZ-depleted BCSC LKO shTAZ and TAZ-overexpressing dBCC TWEEN TAZ. (d) Growth rate of mouse
xenografts generated after orthotopic injection of 5 104 BCSC LKO NT, BCSC LKO shTAZ untreated and treated with doxorubicin (2mg/kg).
Results are mean±s.d. of two independent experiments. In the results shown in panels a and c, paclitaxel was used at 5 ng/ml and
doxorubicin at 15 ng/ml. Cells were treated for 48 h and viability was measured by CellTiter-Glo assay. Both are the mean ±s.d. of three
independent experiments.
TAZ-mediated metastasis and chemoresistance
M Bartucci et al
5
& 2014 Macmillan Publishers Limited Oncogene (2014) 1 – 10
whether TAZ expression is an independent prognostic factor that
could be exploited for clinical use in BC. Thus, to assess whether
our ﬁndings had clinical relevance, we determined TAZ expression
by immunohistochemical staining in 99 consecutive BCs with
complete follow-up data (Supplementary Table S3). Fifty-ﬁve
percent stained positively for TAZ. No signiﬁcant correlation was
observed between TAZ positivity and standard pathological
parameters such as tumor size (P¼ 0.764), lymph node
status (P¼ 0.149), estrogen (ER; P¼ 0.177) and progesterone
(PGR; P¼ 0.219) receptors (Supplementary Table S4). In contrast,
TAZ expression positively correlated with high tumor grade
(P¼ 0.001), HER2 overexpression (P¼ 0.004) and high Ki-67
proliferation index (P¼ 0.008) (Supplementary Table S4), thus
conﬁrming that TAZ expression may be associated with more
aggressive biopathological parameters. Additionally, when our
series of cases were analyzed by unadjusted Kaplan–Meier curves
(Figure 6b), we observed that TAZ expression signiﬁcantly affected
disease-free survival (DFS) (P¼ 0.014). Patients with TAZ-positive
Figure 5. TAZ supports self-renewal capacity and is required for BCSC migration. (a) Tumor-seeding ability of control BCSCs LKO NT and
TAZ-depleted BCSCs LKO shTAZ. The indicated number of cells was orthotopically injected into NSG mice. Left image is representative of
tumor growth monitored by BLI with the color scale depicting the photon flux emitted. Right panel shows a graphical representation of cell-
related tumor growth. Results shown are the mean±s.d. of three experiments performed with groups of three mice each. (b) Representative
image showing morphologic changes in dBCCs following TAZ overexpression. Cell morphology was examined by phase contrast microscopy.
(c) Left: tumor growth curves related to the tumor-seeding ability of dBCCs TWEEN and dBCCs TWEEN TAZ. For each cell population, 5 104
cells were injected into the fat pads of NSG mice. Data are the mean±s.d. of three independent experiments in which three mice/group were
employed. Right: representative BLI image at day 30 post cells implantation indicating the tumorigenic potential of TAZ-overexpressing cells
as compared with control counterpart. (d) In vitro migration ability of TAZ-depleted, TAZ-overexpressing cells and respective controls.
Histogram quantifies relative migratory capacities. (e) Left: in vivo metastatic potential of the cell populations described above. Right:
representative BLI image of metastatic colonization potential of BCSC LKO NT, BCSC LKO shTAZ, dBCC TWEEN and dBCC TWEEN TAZ. Data are
the mean ±s.d. of three independent experiments in which three mice/group were employed.
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tumors exhibited a shorter DFS (51.7% of cancer-free patients)
than those with TAZ-negative BC (78% of cancer-free patients).
As summarized in Table 2, the Cox univariate model highlighted
that nodal status (hazard ratio (HR) 2.56, conﬁdence interval (CI)
95%, 1.32–4.97, P¼ 0.005), tumor grade (HR 0.44, CI 95%,
0.23–0.83, P¼ 0.011) and TAZ positivity (HR 2.35, CI 95%,
1.16–4.77, P¼ 0.017) signiﬁcantly impact DFS. More importantly,
multivariate analysis revealed that nodal status (HR 2.80, CI 95%,
1.40–5.60, P¼ 0.004) and TAZ expression (HR 2.06, CI 95%,
1.01–4.20, P¼ 0.046) were independent negative prognostic
variables inﬂuencing DFS.
DISCUSSION
Understanding the molecular mechanisms responsible for chemo-
resistance and dissemination at secondary sites is critical for the
successful treatment of BC. To date, several lines of evidence
support the idea that CSCs contribute to both therapy resistance
and metastatic dissemination.25–29 However, to validate these
ideas, progress must be made on the molecular mechanisms
governing such processes, starting with the identiﬁcation of genes
and signals that deﬁne CSCs properties. The Hippo transducer TAZ
has been shown to endow CSC properties to non-CSCs cells in BC
cell lines.10 Here, we developed preclinical models based on
Figure 6. TAZ correlates with poor clinical outcome in human breast cancer patients. (a) Representative IHC pictures for TAZ expression in: G3
(panel 1) and G2 (panel 3) invasive human BC samples and corresponding matched lung metastases (panel 2 and 4) showing an increase in
TAZ expression from score 1þ to score 3þ and 2þ , respectively. Acquisition was made with a  20 objective. (b) Kaplan–Meier curve
representing DFS of patients with breast cancer stratified according to TAZ expression status. DFS was calculated from the date of tumor
diagnosis to the date of first recurrence, including local relapses or distant metastases. P-values were calculated using the log-rank test.
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patient-derived BCSCs to investigate the mechanisms underlying
the hierarchical contribution of tumor cells in BC progression and
chemoresistance. We found that TAZ has a key role in the
aggressive behavior of BC and may represent a major determinant
of the unfavorable clinical outcome in advanced BC patients.
Many experimental studies rely on the use of extensively
cultured cell lines that may have lost the main features of cancer
cells from the original tumors. We therefore generated patient-
derived cultures enriched in BCSCs and developed an in vivo
metastatic model that simulates the clinical course of BC patients,
including the formation of primary tumors, surgery and subse-
quent metastatic spreading. This type of model showed that
patient-derived BCSCs are the only population able to metastasize
at distant organs, whereas dBCCs display a weak migratory activity
and do not directly participate in the formation of metastases.
Even though these ﬁndings partially conﬁrm previous results,30
this model provides a considerable tool to investigating different
subpopulations of patient-derived tumor cells in vivo.
Recently, many attempts have been made for dissecting
molecular signals associated with the onset of BC metastases.
The introduction of high-throughput technologies broadened
our knowledge on the genetic pathways associated with the
development and progression of cancer.31 Nevertheless, the
relevance of a single pathway on BC metastatization is still
unclear, especially when considered within the pyramidal
organization of tumors. By taking advantage of gene expression
proﬁling, we documented that the in vivo aggressiveness pattern
(dBCCsoBCSCs) was correlated with the expression of TAZ, which
ranked among the top most signiﬁcantly overexpressed genes in
the CSC compartment. In both normal and cancer cells, TAZ
promotes proliferation, cell migration and invasion, whereas its
expression correlates with the acquisition and maintenance of SC
traits such as self-renewal and chemoresistance.10,32,33 We found
that, unlike in xenografts-derived dBCCs, TAZ is highly expressed
and active in the BCSC counterparts and particularly in in vivo
metastatic derivatives. Exogenous TAZ gain in dBCCs was
associated with the acquisition of a mesenchymal-like pheno-
type, tumorigenic ability and increased cell motility.
Although previous work suggested a relationship between TAZ
expression and poor patient outcome in BC patients,10 a
functional role of TAZ in tumor metastasis has never been
reported before. Here, we show that the appearance of metastases
was remarkably suppressed in TAZ-depleted BCSCs, even when
these cells were injected in high number. In accordance with our
experimental metastatic model, we detected increased TAZ levels
in metastatic lesions as compared with matched primary tumors.
Thus, it is likely that the involvement of TAZ in the metastatic
spreading observed in our preclinical model recapitulates the
events occurring in BC patients. Furthermore, we observed that
high TAZ expression levels in patient tumors was an independent
negative prognostic factor together with the presence of
metastatic lymph nodes and negativity for estrogen receptors.
Table 1. TAZ expression in primary and paired metachronous
metastatic BC
Total
cases, N
Primary breast
cancer
Metastatic breast cancer
TAZ score TAZ score
0 (%) 1þ (%) 2þ (%) 3þ (%)
19 0 6 (32) 5 (26) 6 (32) 2 (10)
16 1þ 0 5 (32) 9 (56) 2 (12)
17 2þ 1 (6) 0 12 (71) 4 (23)
4 3þ 0 0 0 4 (100)
56 7 (13) 10 (18) 27 (48) 12 (21)
TAZ was considered as positive when over 10% of tumor cells displayed
nuclear TAZ immunostaining similar to (score 1þ ) or stronger (score
2þ /3þ ) as compared with normal ducts cells included in the same
section.
Table 2. Uni- and multivariate analyses
Factors Univariate analysis Multivariate analysis
Patients n. 99 HR (95% CI) P-value HR (95% CI) P-value
Tumor size
T2-T4 vs T1 1.83 (0.97–3.47) 0.062
Lymph node status
Positive vs negative 2.56 (1.32–4.97) 0.005 2.80 (1.40–5.60) 0.004
Grading
G1-G2 vs G3 0.44 (0.23–0.83) 0.011
ER
Positive vs negative 0.55 (0.27–1.12) 0.099 0.45 (0.22–0.95) 0.037
PgR
Positive vs negative 0.60 (0.32–1.14) 0.121
HER2
Positive vs negative 1.23 (0.58–2.60) 0.596
Ki-67
High vs low 1.76 (0.90–3.45) 0.097
TAZ
Positive vs negative 2.35 (1.16–4.77) 0.017 2.06 (1.01–4.20) 0.046
Abbreviations: CI, confidence interval; HR, hazard ratio. ER/PgR: negative: o10; positive Z10; HER2 negative: 0/1þ /2þnon amplified; HER2 positive:
2þ amplified/3þ ; KI67 low: p15; high: 415.
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Thus, these data complement and add greater clinical relevance to
previous studies10 by showing that TAZ is overexpressed in high-
grade BC, correlates with overt metastatic lesions in human
patients and is instrumental to incite metastasis in gain- and
loss-of-function assays in mouse models.
Another relevant activity of TAZ in BCSCs concerns the
protection from chemotherapy. Although TAZ does not confer
chemoresistance to dBCCs, TAZ depletion sensitized BCSCs and
relative tumor xenografts to chemotherapeutic drugs, suggesting
that the presence of TAZ in BCSCs contributes signiﬁcantly to drug
resistance in BC. It has been speculated that the biological
plasticity of CSCs may facilitate their survival in a secondary site.
Intriguingly, this and previous studies indicate a scenario in which
the morphological plasticity promoted by EMT (or just loss of
apico-basal polarity) induced TAZ stabilization and, in turn,
acquisition of CSC, drug resistance and metastatic properties.
Future studies are required to identify the downstream targets
through which TAZ induces distinct CSCs properties.
Because the understanding of the biological relevance in cancer
of the Hippo pathway is very recent and rare germinal or somatic
mutations have been described, there are no current drugs now
under development targeting TAZ. However, we believe that TAZ
warrants further clinical investigation in BC, holding the potential
to implement the current pipeline of biomarkers and therapeutic
targets.
MATERIALS AND METHODS
Isolation and cell cultures
BC specimens were obtained upon informed consent from patients
undergoing surgical resection according to the Institutional Ethical
Committee guidelines on human experimentation and the Declaration of
Helsinki. Following surgical specimen dissociation, recovered cells were
cultured in serum-free mediums as previously described.13–15 To obtain
differentiated BC cells (dBCCs), dissociated BCSCs were plated on collagen-
coated plates for 48 h. A layer of Matrigel (BD Biosciences, San Jose, CA,
USA) was subsequently added and cells were grown in complete
mammary epithelial cell growth medium (Lonza, Allendale, NJ, USA).
Colony-forming ability assay
Soft agar colony-forming assays were carried out for untreated BCSCs and
dBCCs as previously described.34
In vivo studies
Animal studies were performed according to the Istituto Superiore di Sanita`
guidelines on animal care under the Italian Ministry of Health authorization
(D.M. n. 224/2011). BCSCs and dBCCs were suspended in 50ml mixed 1:1
with Matrigel (BD Biosciences) and orthotopically injected into the left and
right cleared fat pad of a 6-week-old NOD SCID IL-2Rnull (NSG) mice (Charles
River Laboratories, Wilmington, MA, USA) together with HS-27A stromal cells
(at 2:1 ratio) to humanize the mammary gland. To assess serial
transplantation studies, tumor xenografts derived from distinct patient-
derived BCSC lines were dissociated and 5 104 cells re-injected each time
into the mammary fat pad of the 6-week-old NSG mice. For in vivo tracking,
cells were transfected with lentiviral vector encoding luciferase/enhanced
green ﬂuorescent protein (Luc/EGFP-BCSCs) or luciferase/red ﬂuorescent
protein (Luc/RFP-dBCCs) reporter genes and a total of 104 cells were injected
either intracardially or orthotopically, alone or in deﬁned ratios (1:1).
Bioluminescence imaging was used to assess primary tumor growth and the
onset of distant metastases. A cryogenically cooled imaging system (IVIS 100
Imaging System, Xenogen, Alameda, CA, USA) was employed for whole
body imaging following luciferin (100mg/kg, Caliper Life Science, Hopkin-
ton, MA, USA) administration. Signal intensities were quantiﬁed as the sum
of all detected photons (Living Image Software 2.50, PerkinElmer,
Hopkinton, MA, USA). To discriminate RFP-positive and EGFP-positive cells
in tumor metastases, explanted organs were analyzed under an Olympus
SZX10 stereomicroscope equipped with a ﬂuorescence unit. For chemore-
sistance studies, doxorubicin was intraperitoneally administered 2mg/kg
twice a week for 2 weeks. Tumor growth was measured by an electronic
caliper or evaluated through bioluminescence imaging.
Cell viability assays
For cell viability studies, 3 103 cells/well were seeded in 96-well plates.
Doxorubicin (15 ng/ml) or paclitaxel (5 ng/ml), both from Sigma-Aldrich
(St Louis, MO, USA), were used to evaluate sensitivity to chemotherapy. Cell
viability was evaluated after 48 h as previously described.34
Migration assay
Cell migration was assessed in 24-well transwell boyden chambers (Costar
Scientiﬁc Corporation, Cambridge, MA, USA). Single cells (2 104) were
suspended in a complete growth medium and placed into upper
chambers. After 24 h of incubation, migrated cells were stained with
Coomassie Brilliant Blue and counted under the microscope.
Flow cytometry
For cell sorting of EGFP and RFP tumor cell populations, single-cell
suspensions from primary and metastatic xenografts were collected and
sorted with a FACS Aria (Becton Dickinson, Franklin Lakes, NJ, USA).
Immunoﬂuorescence
For TAZ localization, FPS, FPD and MDA-MB-231 were permeabilized before
incubation with 10 mg/ml mouse anti-TAZ (BD Bioscences). Alexa Fluor 488
and Alexa Fluor 555 (Molecular Probes/Invitrogen, Carlsbad, CA, USA) were
used at 1 mg/ml as secondary antibodies. DAPI (Invitrogen) and Phalloidin-
Alexa Fluor 647 (Molecular Probes/Invitrogen) were used at 1 mg/ml to
visualize nuclei and F-actin cytoskeleton, respectively. Confocal images
were obtained with an Olympus FV-1000 spectral confocal microscope
equipped with an UltraPlan Fluorite 40 NA 1.3 objectives and the software
Olympus Fluoview (Olympus, Tokyo, Japan).
Gene expression proﬁling
Gene array was performed as previously described.35 Brieﬂy, 100 ng of
total RNA was labeled and hybridized to the Affymetrix GeneChip1.0ST
array (Affymetrix, Santa Clara, CA, USA) following the manufacturer’s
instructions. Data analyses were performed by comparing tool classes of
BRB-ArrayTools.
Western blot
For western blot analysis, 20mg of whole-cell lysates were used.
Nitrocellulose membranes were incubated with: anti-YAP/TAZ (D24E4)
and b-actin, (Cell Signaling Technology, Danvers, MA, USA), or Nucleolin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Lentiviral transduction
One cycle of infection with lentiviral supernatants Luc-EGFP and Luc-RFP
was carried out on BCSCs and/or dBCCs culture. EGFP- and RFP-positive
cells were isolated using a FACS Aria. For TAZ overexpression, TAZ cDNA
was cloned into the lentiviral vector pRRL-CMV-PGK-EGFP-WPRE called
TWEEN.36 Two cycles of viral infection (with TWEEN and TWEEN TAZ
supernatants) were performed on Luc/RFP-dBCCs. Lentiviral constructs LKO
NT and LKO shTAZ were obtained as described.10 Selection was carried out
by exposition to puromycine 10 mg/ml (Sigma-Aldrich).
Immunohistochemistry
Immunohistochemistry on xenograft sections was performed on formalin-
ﬁxed, parafﬁn-embedded tissues. Parafﬁn sections (3mm) were treated as
previously described34 and incubated with anti low and medium molecular
weight cytokeratins (CKs, Dako, Fort Collins, CO, USA) and with the
monoclonal antibody anti-TAZ (M2-616, BD Pharmingen, San Jose, CA,
USA). For clinical data, formalin-ﬁxed, parafﬁn-embedded sections were
incubated with anti-ER (6F11, Leica, Milano, Italy), -PgR (1A6, Leica), -HER2
(A0485, Dako), -Ki-67 (MIB-1, Dako) and -TAZ. Immunostaining was
performed using a pH6 antigen retrieval buffer in an automated
autostainer (Bond Max, Menarini Diagnostic srl, Firenze, Italy).
Patients and scoring criteria
A retrospective series of 56 BC patients with matched metachronous
metastases were selected to study TAZ modulation during disease
progression. A series of 99 consecutive BC patients with a median
follow-up of 92 months (CI: 95%; 3.61–126.49) were further investigated
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according to the Ethics Committee of the Regina Elena National Cancer
Institute to evaluate the prognostic role of TAZ expression. TAZ was
considered positive when over 10% of tumor cells displayed nuclear TAZ
immunostaining similar to (score 1þ ) or stronger (score 2þ /3þ ) as
compared with normal ducts cells included in the same section. HER2 was
negative with a score (0 and 1þ ), equivocal (2þ ; to be conﬁrmed by
FISH), or positive (3þ ). ER and PgR were considered positive when410%
of the neoplastic cells showed distinct nuclear immunoreactivity. Ki-67 was
regarded high if 415% of the cell nuclei were immunostained.
Statistical analysis
For in vitro and in vivo studies statistical analyses were performed using
GraphPad Prism version 4 (www.graphpad.com). Statistical signiﬁcance
was determined by two-way analysis of variance with Bonferroni post-test.
P value o0.05*, P value o0.01**, Po0.001***. Statistical analyses for
clinical data were carried out using SPSS software (SPSS version 20.0, SPSS
Inc., Chicago, IL, USA). The DFS curves were estimated by the Kaplan–Meier
method starting from the date of tumor diagnosis to the date of ﬁrst
recurrence. Log-rank test was used to compare survival curves. The HR and
the 95% CI were evaluated for each variable using the Cox univariate
model. A multivariate Cox proportional hazard model was also developed
using stepwise regression (forward selection) with predictive variables that
were signiﬁcant in the univariate analyses. The enter and remove limits
were P¼ 0.10 and P¼ 0.15, respectively.
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